<DOC>
	<DOCNO>NCT00658840</DOCNO>
	<brief_summary>The curative option pancreatic cancer patient surgery , patient within 20 % possible radical surgery . Accordingly , concurrent chemo-radiation therapy generally use palliation unresectable pancreatic cancer patient . So far , use 5-fluorouracil ( 5-FU ) traditional method chemotherapy . However , day , oral anti-cancer medicine , capecitabine ( Xeloda® ) , develop consider alternative medicine 5-fluorouracil ( 5-FU ) . Furthermore , accord recent result clinical trial , clinical use capecitabine ( Xeloda® ) radiation therapy prove effective safe . The purpose trial improve therapeutic effect use proton therapy chemotherapy concurrently .</brief_summary>
	<brief_title>Concurrent Chemo-radiotherapy With Capecitabine Unresectable Locally Advanced Pancreatic Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>There evidence metastatic disease major viscera peritoneal seed Patients biliary gastroduodenal obstruction must drainage prior start chemoradiation All malignant disease must encompassable within single irradiation field ( 15x15cm maximum ) All patient must radiographically assessable disease No previous irradiation plan field Age ≥18 year performance status 0 2 Eastern Cooperative Oncology Group ( ECOG ) score Required Entry Laboratory Parameters WBC count ≥ 2,000/mm3 ; ( ANC &gt; 1,000 ) , hemoglobin level ≥ 7.5 g/dL ; platelet count ≥ 100,000/mm3 ; total bilirubin ≤ 3.0 mg/dL ( Patients elevate bilirubin due obstruction stented bilirubin decreas ≤ 3.0 mg/dL prior study entry ) ; creatinine ≤ 3.0 mg/dL Oral intake ( include Jtube feeding ) ≥ 1,500 calories/day maintain . There evidence metastasis major viscera peritoneal seed . Age &lt; 18 year Previous history RT adjacent plan field poor performance status 3 4 Eastern Cooperative Oncology Group ( ECOG ) score pregnant breast feeding status previous history uncontrolled malignancy within 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>